

MULTIDISCIPLINE PROCEEDINGS OF
**DIGITAL FASHION
CONFERENCE**

KOREA, REPUBLIC OF

Multidiscipline Proceedings of

DIGITAL FASHION CONFERENCE

September 2026 (*Volume 6, No.5*)

Copyright © 2025
By Woongjin Think Big Co., Ltd.
All rights reserved.
Available at digitalfashionsociety.org
Published:
서울 합정역
파주출판도시
ISSN 2466-0744
Seoul
Rebuplic of Korea (ROK),

EDITORIAL BOARD

Katharina Sand

*PhD Candidate - Faculty of Communication, Culture and Society, USI -
Università della Svizzera italiana*

Alice Noris

*PhD Candidate - Faculty of Communication, Culture and Society, USI -
Università della Svizzera italiana*

Michela Ornati

*Faculty of Communication, Culture and Society, USI - Università della
Svizzera italiana*

ELSEVIER



SRN
Societal Research Network

Universal
Impact Factor



MODERN PHARMACEUTICAL EXCIPIENTS AND THEIR IMPACT ON DRUG QUALITY

Usmonova Malikakhon Komiljon kizi

Acting Associate Professor (PhD), Department of Pharmaceuticals
and Chemistry, Alfraganus University
Tashkent, Uzbekistan
m.usmonova@afu.uz

Orcid: <https://orcid.org/0009-0008-0644-4426>

Abstract: The quality of a medicinal product is defined as a reproducible set of critical quality attributes that ensure identity, strength, purity, and performance throughout the shelf life and use conditions. A clear example is the replacement of lactose with mannitol in moisture-sensitive formulations to reduce Maillard-type reactivity with amine-containing APIs. Quantitatively, excipients typically constitute about 80-99% of the mass of many solid oral dosage forms, meaning their variability can dominate batch-to-batch performance. From a scientific standpoint, this repositions excipient selection as a primary design variable within quality-by-design logic, where material attributes are linked to process parameters and final performance [1; 4].

Modern excipients can be classified by function, including diluents, binders, disintegrants, lubricants, surfactants, preservatives, and release-modifying polymers, and each category affects different quality dimensions. For instance, croscopolidone as a superdisintegrant increases tablet porosity upon hydration, accelerating disintegration and reducing dissolution variability compared with older starch-based disintegrants. In numerical terms, typical superdisintegrant levels of 2-5% can decrease disintegration time from above 15 minutes to below 5 minutes under pharmacopeial conditions, improving consistency of in vitro performance. Scientifically, such outcomes are explained by capillary action and swelling pressure, which create microfractures and increase exposed surface area, thereby aligning product performance with dissolution specifications [2; 6].

Scientifically, the phenomenon is rationalized by radical chain mechanisms and autocatalysis, emphasizing why supplier qualification, impurity monitoring, and excipient specifications are integral to quality assurance [3; 5].

The mechanism operates through powder flow, compressibility, lubrication, and granule strength, which shape tablet weight variation and dose uniformity. For example, microcrystalline cellulose improves direct compression by providing plastic deformation behavior, whereas dicalcium phosphate contributes brittle fracture; the balance affects compactibility and friability. Quantitatively, acceptable weight variation and content uniformity targets often require relative standard deviations of a few percent, and modest changes in lubricant level, such as magnesium stearate from 0.5% to 1.5%, can measurably reduce tablet hardness and prolong dissolution. Scientifically, this is explained by hydrophobic film formation on particles and reduced interparticle bonding, illustrating that excipient concentration is a mechanistic lever rather than a merely empirical setting [1; 2].

Stability as a quality pillar can be systematically analyzed via the chemical equation of hydrolysis and the controlling influence of excipients on water availability. The definition of hydrolytic instability encompasses cleavage reactions that change assay and generate impurities, and excipients can either buffer the microenvironment or bind water to mitigate risk. The mechanism involves water activity modulation and local pH

shifts within pores and at particle interfaces, where degradation can proceed faster than in bulk. [3; 5].

A comparative analysis of modern excipient innovations shows a shift from single-function materials toward multifunctional and engineered excipients tailored for specific processes and performance. The definition of engineered excipients includes co-processed particles, functionalized polymers, and lipid-based carriers that combine flow, compressibility, and release control in one material. The mechanism is achieved through controlled particle engineering, such as spray drying or co-processing, which adjusts porosity, surface area, and binding sites. For example, co-processed excipients combining microcrystalline cellulose with colloidal silicon dioxide improve flow and compaction simultaneously, reducing the need for multiple additives. Quantitatively, improved flow can be expressed as reduced angle of repose or improved flow function coefficients, translating into fewer feeding interruptions and more consistent tablet weights at production scale. Scientifically, this reflects how material design aligns microstructure with macroscopic process performance, consistent with modern pharmaceutical engineering principles [2; 4].

A concise tabular synthesis helps connect excipient classes to quality impacts and typical risks, thereby supporting structured decision-making in formulation development. The definition of such a synthesis is an evidence-based mapping between material function and quality attributes, and its mechanism is to make trade-offs explicit for compatibility and control strategies. For instance, disintegrants accelerate release but can increase moisture uptake; surfactants enhance solubility but may carry peroxide impurities; preservatives protect microbiological quality but can interact with packaging or proteins [3; 6].

The mechanism behind this shift includes improved characterization tools such as differential scanning calorimetry, dynamic vapor sorption, and advanced chromatography, which reveal interactions previously invisible in routine testing. For example, the identification of amorphous-crystalline transitions in solid dispersions and their dependence on polymer grade has made excipient control central to lifecycle management. Quantitatively, modern characterization can detect low levels of moisture sorption or glass transition changes that predict stability outcomes, allowing earlier risk mitigation than classical end-product testing. Scientifically, this trajectory supports the thesis that excipient science is now inseparable from drug quality science, and that robust formulations arise from measured control of excipient attributes and interactions [4; 7].

In conclusion, modern excipients define drug quality through interconnected effects on stability, performance, manufacturability, and analytical control, making them functional determinants rather than neutral components. Their mechanisms of action operate at molecular, interfacial, and microstructural levels, where small changes in impurity profiles, moisture behavior, or surface properties can translate into significant shifts in dissolution, degradation, or process robustness. Practical formulation outcomes demonstrate that systematic excipient selection and specification, grounded in compatibility evaluation and material science, improves reproducibility and reduces quality risks across the product lifecycle. The integrated view developed here synthesizes excipient functionality with quality attributes to support rational design of high-quality medicines in contemporary pharmaceutical practice.

References:

1. Allen L. V. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Wolters Kluwer; 2019. 720 p.
2. Aulton M. E., Taylor K. M. G. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Edinburgh: Elsevier; 2018. 912 p.
3. Waterman K. C., Adami R. C. Accelerated aging: prediction of chemical stability of pharmaceuticals. New York: CRC Press; 2016. 356 p.
4. Qodirov A. A., Karimov S. B. Dori vositalari texnologiyasida yordamchi moddalar: tanlash va sifat nazorati. Toshkent: Abu Ali ibn Sino nomidagi nashriyot; 2020. 240 b.
5. Вайнберг Ю. И., Глазкова И. В. Вспомогательные вещества в технологии лекарственных форм: совместимость и стабильность. Москва: ГЭОТАР-Медиа; 2017. 288 с.
6. Rowe R.C., Sheskey P.J., Quinn M.E. Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press; 2012. 1064 p.
7. Saha S., Shahiwala A. Multifunctional excipients for solid dosage forms: a review. Amsterdam: Elsevier; 2021. 180 p.

ELSEVIER



SRN
Science & Research Network

Universal
Impact Factor